Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7-targeted CAR-T Cells for R/R PTCL
NCT07143929Phase 1Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in peripheral T-cell lymphoma (PTCL), sponsored by Peking University People's Hospital. Primary endpoint: Dose-limiting toxicity at 28 days. Started Aug 2025; status: recruiting.
02
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07143929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07143929.